Literature DB >> 33854988

A randomized controlled trial to compare the efficacy of regenerated and non-regenerated oxidized cellulose gauze for the secondary treatment of local bleeding in patients undergoing hepatic resection.

Chengshuo Zhang1, Dazhi Fu1, Fengshan Wang1, Xinping Zhong1, Lei Yang1, Gang Wu1, Baifeng Li1, Jialin Zhang1.   

Abstract

PURPOSE: Oxidized cellulose is available in many forms, but manufactured using either a regenerated or non-regenerated process. In this study, we evaluated the effects of 2 different hemostatic agents for the treatment of local bleeding in patients undergoing hepatic resection.
METHODS: This was a monocentric, parallel-group, randomized, and controlled clinical trial to compare oxidized regenerated cellulose gauze (ORCG) with oxidized non-regenerated cellulose gauze (ONRCG) in patients undergoing hepatectomy. The primary endpoint was the time to hemostasis at the target bleeding site. The secondary endpoints were the postoperative drainage volume on the first 2 days after surgery and the hospital stay.
RESULTS: There was no significant difference between the ORCG and ONRCG groups in time to hemostasis from column analysis (238.8 ± 121.6 seconds vs. 193.7 ± 85.3 seconds, P = 0.068), and there were no differences in the rates of hemostatic success between the 2 groups at 120 seconds (18.4% vs. 24.3%; odds ratio [OR], 0.703; 95% confidence interval [CI], 0.231-2.136) and 300 seconds (71.1% vs. 89.2%; OR, 0.298; 95% CI, 0.085-1.041). However, the ONRCG group was superior to the ORCG group in hemostasis according to the survival analysis (log-rank test, P = 0.044). Moreover, there were also no significant differences between the 2 groups in postoperative drainage volume on the first 2 days (P = 0.436, P = 0.381) and hospital stay (P = 0.537, P = 0.200).
CONCLUSION: ONRCG was not inferior to ORCG as a hemostatic agent in patients undergoing liver resection.
Copyright © 2021, the Korean Surgical Society.

Entities:  

Keywords:  Hemostasis; Hepatectomy; Oxidized cellulose; Surgicel; Traumastem

Year:  2021        PMID: 33854988      PMCID: PMC8019981          DOI: 10.4174/astr.2021.100.4.193

Source DB:  PubMed          Journal:  Ann Surg Treat Res        ISSN: 2288-6575            Impact factor:   1.859


INTRODUCTION

Intraoperative bleeding is common in patients undergoing hepatic resection [1]. Secondary adverse events significantly increase when bleeding occurs during surgical procedures. Increasing evidence shows that blood loss and its related transfusion is an independent risk factor for recurrence of malignant tumors [23]. Therefore, the control of bleeding is a major concern for surgeons performing hepatectomy. Many distinct surgical techniques have been used to control bleeding in patients undergoing hepatectomy. These techniques include controlled low central venous pressure strategies [4], diverse hepatic vascular occlusion techniques [56], and the use of various physical parenchyma transection and hemostatic apparatus [78910]. In addition, hemostatic, sealant, and adhesive products are also widely applied to control surgical bleeding when standard techniques are insufficient. Topical hemostats are agents that stop bleeding by inducing blood to clot. Oxidized cellulose, a sort of mechanical hemostatic material, predominantly forms a block to stop the blood flow and provides a surface to induce more rapid clotting [11]. It was marketed for the first time in 1945 and has been widely used for its convenience, biocompatibility, and bactericidal properties [12]. It is currently available in many commercial products and manufactured using either a regenerated or non-regenerated process. The physicochemical properties and hemostatic efficacy of oxidized regenerated cellulose gauze (ORCG) and oxidized non-regenerated cellulose gauze (ONRCG) have been well documented using in vitro tests and animal models, and ONRCG is seemingly superior to ORCG in terms of hemostasis [13]. However, no clinical study has been performed to verify this. Therefore, the objective of this prospective randomized study was to assess the hemostatic efficacy of ORCG vs. ONRCG for hemostasis of local bleeding in patients undergoing hepatic resection.

METHODS

Study population

In this prospective randomized study, 81 patients (18–75 years old) with masses undergoing hepatic resection for any potential disease in the First Hospital of China Medical University, Shenyang, P.R. China, during a 10-month period from August 2017 to May 2018 were allocated randomly to apply ORCG (Surgicel Original, Ethicon Inc., San Angelo, TX, USA) or ONRCG (Traumastem TAF, Bioster a.s., Prague, Czech Republic) for the treatment of local bleeding. Patients were randomized to groups using a web-based calculator available at http://www.lvsezhifei.com.

Oxidized cellulose gauze

The ORCG (Surgicel Original) is white to pale yellow. In this study, 5.1 × 7.6-cm sized patches were used for each patient. The ONRCG (Traumastem TAF) is white to light yellow. A pattern of 7 × 5-cm product was used for each patient in this study. Both oxidized celluloses are sterile absorbable knitted fabrics with a faint caramel-like smell. Both of these products are strong and can be cut or sutured without fraying. When the gauzes are soaked with blood, they then turn into a black gelatinous mass that aids in the formation of a clot to control local hemorrhage.

Inclusion and exclusion criteria

Patients who gave informed consent, aged 18–75 years, with selective removal of an equivalent tissue volume of at least 1 anatomical hepatic segment qualified for inclusion in this study. Precise liver resection was performed with a physical parenchyma transection apparatus, a cavitron ultrasonic surgical aspirator. The topical hemostatic gauzes were necessary when minor-to-moderate amounts of bleeding (oozing/diffuse) continued at the surgical site after the end of the primary hemostatic procedures to control arterial pulsating bleeding and venous hemorrhage using vascular clips, sutures, ligatures, point electrocautery, and argon beam coagulation at the end of the surgery. Exclusion criteria were surgical contraindication or indication for emergency surgery, participation in other clinical trials in the past 3 months, obvious hematologic disorders, brain disease or mental disorder (abnormal judgment) that prevents cooperation, severe cardiac disease, severe metabolic disease or endocrine disorders, asthma or allergies, immunodeficient patients (acquired immune deficiency syndrome), skin infection in the targeted incisional area, pregnancy, or breastfeeding females or fertility planning within 1 year after the surgery. Intraoperative exclusion criteria included unresectable liver lesions and the application of other topical hemostatic materials.

Ethical issues

This study was a monocentric, pragmatic, parallel-group, prospective, randomized, and controlled clinical trial. It was approved by the Ethics Committee of the First Hospital of China Medical University, Shenyang, P.R. China with the institution review board number 2017QL013-KS-1 (registered under ClinicalTrials.gov Identifier no. NCT03489070). Written informed consent from every patient was collected before enrollment, and the patients were entitled to withdraw from the trial at any time.

Objectives

The primary endpoint of this study was the time to hemostasis. Specifically, a representative liver cut surface (prominent bleeding site) was applied with 2 felts of hemostatic gauze with even finger gentle pressing under aseptic conditions, then it was left untouched and observed for 10 minutes. Vascular inflow occlusion of the liver was allowed if necessary, but it was open for evaluation of hemostatic efficacy. Hemostatic time was measured starting from when the hemostatic gauze was applied. Time to hemostasis was recorded in seconds, and the maximum time to hemostasis was 600 seconds. Hemostasis success was achieved based on the following requirements. First, there was no visible bleeding or minimal ooze from the observational site. Second, sterile dry gauze was bloodless after wiping the hemostatic gauze repeatedly. Third, a local scar was formed when the hemostatic gauze was gently removed from the wound. The secondary endpoints were the postoperative drainage volume on the first 2 days after surgery, the hospital stay, and the postoperative hospital stay.

Blinding

Blinding of the surgeons was impossible due to the difference in gross appearance of the 2 agents (texture and size). Those performing the postoperative evaluation were completely blinded as to which hemostatic gauze was used for each patient.

Statistical analysis

The sample size of 78 patients (39 in each group) was set to ensure 95% power to access a statistically significant result at the 5% level, assuming that 30% of the patients in the ORCG group and 67% of the patients in the ONRCG group achieved hemostasis within 10 minutes. The sample size calculation was based on the statistics of continuity corrected chi-square (36 patients per group) and assumed to approximate a 5% dropout rate. IBM SPSS Statistics ver. 22.0 (IBM Corp., Armonk, NY, USA) was used for statistical analyses in this study. Quantitative variables with normal distribution are given as mean ± standard deviation, otherwise as median and range. Comparisons were performed between the 2 groups using independent Student t-test or Mann-Whitney test for quantitative variables, and qualitative variables were compared by chi-square test. The primary endpoint was analyzed using curve analysis, and the result was compared using the log-rank test. Statistical differences were considered significant when P < 0.05 (2-sided significance testing).

RESULTS

In this study, a total of 81 potential patients undergoing hepatic resection were screened, 78 of whom were enrolled and randomized, and 75 finally completed treatment with ORCG (n = 38) or ONRCG (n = 37) for local hemostasis at the late stage of surgery. A study flowchart is shown in Fig. 1.
Fig. 1

Flowchart of the patients. ORCG, oxidized regenerated cellulose gauze; ONRCG, oxidized non-regenerated cellulose gauze; AE, adverse events.

The baseline characteristics of patients between the 2 groups are listed in Table 1. The median age of all patients was 56 years (range, 25–73 years), and 53.3% (40 of 75) were male, and liver cirrhosis was present in 26.7% of patients. Hepatocellular carcinoma and hepatic hemangioma (62.7%, 47 of 75) were the most common reason for liver resection. Traditional laparotomy, laparoscopy, and robotic surgery were used to perform liver resection according to the characteristics, size, and location of the lesions, and the median operative time was 170 minutes (60–448 minutes). The preoperative and intraoperative parameters were similar between the 2 groups.
Table 1

Baseline characteristics of patients

Values are presented as number only, median (range), number (%), or mean ± standard deviation.

ORCG, oxidized regenerated cellulose gauze; ONRCG, oxidized nonregenerated cellulose gauze.

a)Hepatic angiomyolipoma, 1; hepatic cyst, 1; and hepatic vascular tumor, 1. b)Hepatobiliary cystadenoma. c)Gallbladder carcinoma. d)Hepatic sarcomatoid carcinoma. e)Liver metastasis of colorectal cancer, 2 and liver metastasis of ovarian carcinoma 1. f)Liver metastasis of colorectal cancer, 1 and liver metastasis of gastrointestinal stromal tumor, 1.

There was no significant difference between the ORCG and ONRCG groups in time to hemostasis from column analysis (238.8 ± 121.6 seconds vs. 193.7 ± 85.3 seconds, P = 0.068) (Table 2, Fig. 2A). In addition, there were no differences in the rates of hemostatic success between the 2 groups (odds ratio [OR], ORCG/ONRCG) at 120 seconds (18.4% vs. 24.3%; OR, 0.703; 95% confidence interval [CI], 0.231–2.136) and 300 seconds (71.1% vs. 89.2%; OR, 0.298; 95% CI, 0.085–1.041) (Table 2, Fig. 2B). However, the ONRCG group seemed to be superior to the ORCG group in hemostasis from a curve analysis (log-rank test, P = 0.044) (Fig. 2C).
Table 2

Postoperative profiles

Values are presented as mean ± standard deviation, number (%), or median (range).

ORCG, oxidized regenerated cellulose gauze; ONRCG, oxidized nonregenerated cellulose gauze; POD, postoperative day.

Fig. 2

Hemostatic time in patients undergoing hepatectomy between the 2 groups. (A) The scatter plot of the time to hemostatic in patients undergoing hepatectomy. (B) Hemostatic success at 120, 300, and 600 seconds after treatment in patients undergoing hepatic resection. (C) Time to hemostasis (Kaplan-Meier) in patients undergoing hepatectomy. ORCG, oxidized regenerated cellulose gauze; ONRCG, oxidized non-regenerated cellulose gauze.

The median postoperative drainage volume was 68 mL (0–885 mL) in the ORCG group and 75 mL (0–500 mL) in the ONRCG group on the first day after surgery. On the second day after surgery, the median postoperative drainage volume was 20 mL (0–570 mL) in the ORCG group and 40 mL (0–1,160 mL) in the ONRCG group. There were no significant differences between the 2 groups on the first 2 days after the operation (P = 0.436, P = 0.381) (Table 2). The total hospital stay was 17 days (9–39 days) in the ORCG group and 18 days (8–47 days) in the ONRCG group. There was no significant difference between the groups (P = 0.537). The postoperative hospital stay was 9 days (5–22 days) in the ORCG group and 9 (4–26) in the ONRCG group. The difference was also not significant between the groups (P = 0.200) (Table 2). Surgical complications were evaluated by the Clavien-Dindo classification [14], and a surgical complication with a score higher than grade II was not found in this study. Furthermore, the parameters of laboratory examinations including blood routine, liver function, renal function, coagulation function, and infectious markers did not show any significant differences between the 2 groups perioperatively (Supplementary Table 1).

DISCUSSION

The liver is predisposed to bleed diffusely because of its extensive vessels and inferior vascular contractility [15]. Postoperative morbidity and mortality are closely related to blood loss during hepatic resection [16]. It is therefore challenging to control bleeding after the resection of liver parenchyma intraoperatively. In the past 3 decades, new surgical techniques, apparatus, and products with hemostatic, sealant, and adhesive qualities have been used to substantially reduce bleeding and its related complications during liver resection. Among these, oxidized cellulose including regenerated and nonregenerated hemostatic agents are widely used [1317]. It has been demonstrated using scanning electron microscopy that different fiber structures exist between ORCG and ONRCG, while they have similar pH in human pooled plasma and undifferentiated bactericidal effectiveness according to colonyforming unit assays. Oxidized non-regenerated cellulose seems superior to oxidized regenerated cellulose in animal hepatic models in terms of hemostasis, which is likely due to its frayed fiber structure and greater material density [18]. The greater surface area of oxidized non-regenerated cellulose can facilitate bleeding sites to clot more rapidly. However, no clinical study has been performed to evaluate the efficacy of regenerated and non-regenerated oxidized cellulose hemostatic agents in controlling bleeding for patients undergoing hepatic resection. In this study, we set the time to hemostasis as the primary endpoint, and postoperative drainage volume and duration of hospital stay as the secondary endpoints for comparing the efficacy of these 2 gauzes. There was no significant difference between the ORCG and ONRCG groups in time to hemostasis from column analysis; however, ONRCG was slightly superior to ORCG for achieving hemostasis in patients undergoing hepatic resection from a curve analysis. Moreover, there were also no significant differences between the 2 groups in postoperative drainage volume on the first 2 days or in hospital stay. The Surgicel Original absorbable hemostat has been proven effective and safe for more than 50 years. However, the absorption of oxidized cellulose can be lessened in cauterized areas, and adverse events from foreign body reactions have been reported in patients using oxidized cellulose [19]. The removal of any excess gauze before surgical closure has been taken as a precaution to facilitate absorption and minimize the possibility of foreign body reactions. Traumastem TAF is an agent used to stop capillary, venous, and very minor arterial bleeding, and has been adopted successfully to reduce postoperative bleeding in patients who have undergone thoracic surgery, neurosurgery, and liver resection [202122]. It has been reported to fully biodegrade by 8 days; however, the residual reticulum of oxidized cellulose can be detected in some individuals by ultrasound at postoperative 1-month follow-up. The absorption of oxidized non-regenerated cellulose will depend on several factors, including the felts used, wound bed, and degree of saturation with blood [23]. Therefore, care should be taken not to apply the gauze too tightly around the first and second hepatic portal area, as it may cause a stenotic effect on vessels and ducts after liver resection. The vascular intervention or reoperation for postoperative bleeding is rare occurrence in patients undergoing liver resection in our department. There was no delayed bleeding or complication due to postoperative bleeding in any group from this clinical trial. In addition, we set some objective indicators and did not find any differences between the 2 groups in terms of postoperative drainage volume, hospital stay, or laboratory examinations indexes such as blood routine, liver function, renal function, coagulation function, or infectious markers. This study does have some limitations that need to be considered when interpreting the findings. First, while our findings indicate relatively superior results for ONRCG in comparison to ORCG, the difference was not obvious. The sample size in our study was relatively limited, which could weaken the statistical power of our conclusions. Furthermore, the span of postoperative observation points between individuals was large. The rationality of the study design and the compliance of the patient follow-up should be improved. In addition, other indexes of gauze quality such as flexibility, biocompatibility, absorbability, adhesiveness, and cost were not compared in this study, and this data should be supplemented by future studies. In conclusion, the results of this study indicate slight discrepancies between the 2 groups, and ONRCG was not inferior to ORCG as a secondary hemostatic agent of operative sites in patients undergoing liver resection.
  22 in total

1.  [Surgical techniques in hepatic resections: Ultrasonic aspirator versus Jet-Cutter. A prospective randomized clinical trial].

Authors:  H G Rau; M W Wichmann; S Schinkel; E Buttler; S Pickelmann; R Schauer; F W Schildberg
Journal:  Zentralbl Chir       Date:  2001-08       Impact factor: 0.942

Review 2.  State-of-the-art review: Hemostats, sealants, and adhesives II: Update as well as how and when to use the components of the surgical toolbox.

Authors:  William D Spotnitz; Sandra Burks
Journal:  Clin Appl Thromb Hemost       Date:  2010-08-10       Impact factor: 2.389

Review 3.  Controlled low central venous pressure reduces blood loss and transfusion requirements in hepatectomy.

Authors:  Zhi Li; Yu-Ming Sun; Fei-Xiang Wu; Li-Qun Yang; Zhi-Jie Lu; Wei-Feng Yu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

4.  Exploration on surgical-related factors influencing HCC patients prognosis.

Authors:  Zhou Lei; Liu Chang; Meng Fan-Di; Wu Qi-Fei; Tian Feng; Tai Ming-Hui; Wei Ji-Chao; Lei Lei; Wang Rui-Tao; Qu Kai
Journal:  Hepatogastroenterology       Date:  2012 Jul-Aug

5.  Randomized clinical trial of the effect of a saline-linked radiofrequency coagulator on blood loss during hepatic resection.

Authors:  J Arita; K Hasegawa; N Kokudo; K Sano; Y Sugawara; M Makuuchi
Journal:  Br J Surg       Date:  2005-08       Impact factor: 6.939

6.  Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years.

Authors:  Matteo Cescon; Gaetano Vetrone; Gian Luca Grazi; Giovanni Ramacciato; Giorgio Ercolani; Matteo Ravaioli; Massimo Del Gaudio; Antonio Daniele Pinna
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

7.  Comparison of regenerated and non-regenerated oxidized cellulose hemostatic agents.

Authors:  K M Lewis; D Spazierer; M D Urban; L Lin; H Redl; A Goppelt
Journal:  Eur Surg       Date:  2013-07-04       Impact factor: 0.953

8.  Application of temporary inflow control of the Glissonean pedicle method provides a safe and easy technique for totally laparoscopic hemihepatectomy by Glissonean approach.

Authors:  Nuri Lee; Chan Woo Cho; Jong Man Kim; Gyu-Seong Choi; Choon Hyuck David Kwon; Jae-Won Joh
Journal:  Ann Surg Treat Res       Date:  2017-04-27       Impact factor: 1.859

9.  A foreign body reaction to Surgicel® in a lymph node diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.

Authors:  Diana Badenes; Lara Pijuan; Víctor Curull; Albert Sánchez-Font
Journal:  Ann Thorac Med       Date:  2017 Jan-Mar       Impact factor: 2.219

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more
  2 in total

1.  The efficacy of oxidized regenerated cellulose (SurgiGuard®) in breast cancer patients who undergo total mastectomy with node surgery: A prospective randomized study in 94 patients.

Authors:  Kug Hyun Nam; Joon-Hyop Lee; Yoo Seung Chung; Yong Soon Chun; Heung Kyu Park; Yun Yeong Kim
Journal:  PLoS One       Date:  2022-05-27       Impact factor: 3.752

2.  A multicenter, prospective, randomized clinical trial of marine mussel-inspired adhesive hemostatic materials, InnoSEAL Plus.

Authors:  Gyu-Seong Choi; Seoung Hoon Kim; Hyung Il Seo; Je Ho Ryu; Sung Pil Yun; Mi-Young Koh; Moon Sue Lee; Haeshin Lee; Jae Hun Kim
Journal:  Ann Surg Treat Res       Date:  2021-10-29       Impact factor: 1.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.